Investigating the Effect of Aging on the Pharmacokinetics and Tumor Delivery of Nanomaterials using Mathematical Modeling

The application of nanomedicine for diagnosis and treatment of cancer has immense potential, but has witnessed only limited clinical success, in part due to insufficient understanding of the role of nanomaterial properties and physiological variables in governing nanoparticle (NP) pharmacology. Here, we present a multiscale mathematical model to examine the effects of physiological changes associated with patient age on the pharmacokinetics and tumor delivery efficiency of NPs. We show that physiological changes due to aging prolong the residence of NPs in the systemic circulation, thereby improving passive accumulation of NPs in tumors.Clinical Relevance — Understanding the effect of inter-individual variability on the pharmacological behavior of nanomaterials will improve their clinical translatability.

[1]  Vittorio Cristini,et al.  Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics , 2018, Nature Communications.

[2]  Dhaval K. Shah,et al.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  Colin M. Wilson,et al.  Predicting breast cancer response to neoadjuvant chemotherapy based on tumor vascular features in needle biopsies. , 2019, JCI insight.

[4]  V. Cristini,et al.  Mathematical Modeling to Address Challenges in Pancreatic Cancer. , 2019, Current topics in medicinal chemistry.

[5]  Joseph D Butner,et al.  Simulating cancer growth with multiscale agent-based modeling. , 2015, Seminars in cancer biology.

[6]  Mauro Ferrari,et al.  Theory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell Kill , 2016, PLoS Comput. Biol..

[7]  Johan Gabrielsson,et al.  Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2002 .

[8]  Vittorio Cristini,et al.  Understanding Drug Resistance in Breast Cancer with Mathematical Oncology , 2014, Current Breast Cancer Reports.

[9]  R. Jain,et al.  Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks in vivo , 2010 .

[10]  V. Cristini,et al.  Size-Optimized Ultrasmall Porous Silica Nanoparticles Depict Vasculature-Based Differential Targeting in Triple Negative Breast Cancer. , 2019, Small.

[11]  Zhihui Wang,et al.  Integrated PK-PD and agent-based modeling in oncology , 2015, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  Mithat Gönen,et al.  Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe , 2014, Science Translational Medicine.

[13]  Xh Huang,et al.  Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2010 .

[14]  Vittorio Cristini,et al.  Mathematical modeling in cancer nanomedicine: a review , 2019, Biomedical Microdevices.

[15]  U. Mahlknecht,et al.  Age-related changes in peripheral blood counts in humans. , 2010, Experimental and therapeutic medicine.

[16]  C. Röcker,et al.  Modeling receptor-mediated endocytosis of polymer-functionalized iron oxide nanoparticles by human macrophages. , 2011, Biomaterials.

[17]  R. Sidman,et al.  Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release , 2016, Proceedings of the National Academy of Sciences.

[18]  Hemant Sarin,et al.  Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability , 2010, Journal of angiogenesis research.

[19]  C. Brinker,et al.  Image‐guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies , 2020, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[20]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[21]  Joseph D Butner,et al.  A mathematical model to predict nanomedicine pharmacokinetics and tumor delivery , 2020, Computational and structural biotechnology journal.

[22]  H. Buhr,et al.  Measurement of blood flow in pancreatic exchange capillaries with FITC-labeled erythrocytes. , 1995, Microvascular research.

[23]  Clement Kleinstreuer,et al.  Direct nanodrug delivery for tumor targeting subject to shear-augmented diffusion in blood flow , 2018, Medical & Biological Engineering & Computing.

[24]  Vittorio Cristini,et al.  Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response. , 2013, ACS nano.

[25]  Mauro Ferrari,et al.  A modeling platform for the lymphatic system. , 2020, Journal of theoretical biology.

[26]  Jason L. Townson,et al.  Understanding the Connection between Nanoparticle Uptake and Cancer Treatment Efficacy using Mathematical Modeling , 2018, Scientific Reports.

[27]  T. Eissing,et al.  Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals , 2016, Clinical Pharmacokinetics.

[28]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[29]  Vittorio Cristini,et al.  Multiscale cancer modeling. , 2010, Annual review of biomedical engineering.

[30]  Vittorio Cristini,et al.  An Introduction to Physical Oncology: How Mechanistic Mathematical Modeling Can Improve Cancer Therapy Outcomes , 2017 .